If my patient is a candidate for sino-nasal surgery, why would I consider a biologic like DUPIXENT?

In DUPIXENT’s SINUS-52 trial, 59% of patients had 1 or more surgeries. With DUPIXENT, 83% fewer patients required sino-nasal surgery with DUPIXENT 300 mg Q2W + INCS (HR: 0.17 [95% CI: 0.07, 0.46]).^1,a

DUPIXENT provided a 76% reduction in SCS use or CRSwNP surgery at Week 52 with DUPIXENT 300 mg Q2W + INCS vs placebo + INCS (HR: 0.24 [95% CI: 0.17, 0.35]).

^a Individually, need for sino-nasal surgery was not a multiplicity-adjusted endpoint.⁶

CRSwNP, chronic rhinosinusitis with nasal polyposis; HR, hazard ratio; INCS, intranasal corticosteroid; Q2W, once every 2 weeks; SCS, systemic corticosteroid.

Learn more about sino-nasal surgery reduction